Fremanezumab
Fremanezumab is a monoclonal antibody medication used for the preventive treatment of migraine in adults. It works by targeting and blocking calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks. This treatment is administered by subcutaneous injection and is typically prescribed for patients who experience chronic or episodic migraine.
Fremanezumab is a CGRP inhibitor injection used to prevent migraine headaches in adults.
Key facts at a glance
- ATC
- N02CD03
- RxNorm
- 2056691
- Generic
- Fremanezumab
- Class
- atc-n02
- Brands
- Ajovy
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 225mg monthly
- Maximum
- consult physician
- Frequency
- once monthly (or 675mg every 3 months)
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- Not FDA approved for pediatric use
- Maximum
- consult physician
- Frequency
- N/A
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 225mg monthly
- Maximum
- consult physician
- Frequency
- once monthly (or 675mg every 3 months)
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh potential risks to fetus
regular prenatal monitoring recommended
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
continue only if benefits outweigh potential risks
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
use only if benefits outweigh potential risks
regular fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment
discontinue breastfeeding or interrupt treatment based on benefit-risk assessment
monitor infant for potential effects
pediatric_age
under 18 yearsnot recommended
not approved for use in pediatric patients; safety and efficacy not established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
65 years and olderno adjustment
no dosage adjustment required; monitor for adverse effects
routine monitoring
renal_impairment
mild moderateno adjustment
no dose adjustment required for mild to moderate renal impairment
routine monitoring
renal_impairment
severeno adjustment
use with caution; limited clinical data available
enhanced monitoring recommended
Use with caution and monitor for adverse effects.
hepatic_impairment
mild moderateno adjustment
no dose adjustment required for mild to moderate hepatic impairment
routine monitoring
hepatic_impairment
severeno adjustment
use with caution; limited clinical data available
enhanced monitoring recommended
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Calcitonin gene-related peptide inhibitor monoclonal antibody
FDA approval year
Initial FDA approval for Fremanezumab
Common uses
Approved therapeutic indication for episodic and chronic migraine
Route of administration
Method of drug delivery
Fremanezumab is indicated for the preventive treatment of migraine in adults, including both chronic migraine (15 or more headache days per month) and episodic migraine (fewer than 15 headache days per month).
Fremanezumab is a humanized monoclonal antibody that binds specifically to the calcitonin gene-related peptide (CGRP) ligand, preventing CGRP from binding to its receptor. By blocking this neuropeptide, which is involved in the inflammation and pain signaling associated with migraines, the medication helps reduce the frequency and severity of migraine attacks.
Fremanezumab is administered as a subcutaneous injection, either monthly or quarterly. As a biologic medication, it should not be stopped abruptly without medical consultation. Common side effects may include injection site reactions. Patients should be monitored for hypersensitivity reactions during treatment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy